BioSpace News Archive

Transaction to Create a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates

TransCelerate BioPharma Inc. , a non-profit collaboration comprised of 20 of the largest biopharmaceutical companies, today announced that it is expanding access to COVID-19-related patient-level clinical data sharing via DataCelerate® to non-member companies. In addition, TransCelerate will

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced it is collaborating with Biomedical Advanced Research and Development Authority ( BARDA ), a component of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to further advance the de

Units Offer Hands-On Education Around All Treatment Modalities Including Home Dialysis for Patients Recently Diagnosed with Kidney Failure

Saint-Gobain Life Sciences and Kanyr Pharma partner with clinical experts at the Research Institute of McGill University Health Centre and engineers at McGill to develop new cell culture technologies.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.18 per share.

State-of-the-art lab and office space is home to biotech companies that have raised more than $31 million

Dr Carmen Escuriola-Ettingshausen and Dr Robert Sidonio are pleased to announce that MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) has been approved in the United States and Europe and is now recruiting participants.

NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the FDA has provided necessary feedback regarding the design of NANORAY-312, the Company’s pivotal phase III global registration trial in head and neck cancer.

Until President Trump suggested that hydroxychloroquine (HCQ, Plaquenil™) might help COVID-19 patients, it was generally considered a very safe drug, observes the Association of American Physicians & Surgeons (AAPS).